Information updates

ASCIA information about COVID-19

12 March 2020

ASCIA has developed the following resources in response to the COVID-19 infectious respiratory disease outbreak caused by the most recently discovered coronavirus, which are available open access on the ASCIA COVID-19 webpage https://www.allergy.org.au/members/covid-19:

  • Information about COVID-19 for people with primary and secondary immunodeficiencies.
  • Checklist of actions to reduce the spread of COVID-19.
  • FAQ (frequently asked questions and answers) about COVID-19. 

The situation regarding COVID-19 is rapidly changing, so it is important to check the ASCIA website  https://www.allergy.org.au/members/covid-19 for updated resources and further information. 

Continue reading

Supply update - EpiPen® adrenaline (epinephrine) autoinjectors

9 March 2020: 

Mylan Australia has advised that despite there being sufficient supply of EpiPen®. unprecedented, disproportionate demand has meant that some pharmacies are experiencing supply delays and are seeing stock outages at some wholesalers, 

To ensure equitable distribution of EpiPen® nationally, Mylan has commenced controlled supply to pharmacies. Pharmacies now need to call the Mylan EpiPen Customer Service hotline on 1800 931 625 to place an order for EpiPen®. Only orders placed by pharmacies via Mylan will be processed and stock will still be delivered to pharmacies via wholesalers.

For regular updates about adrenaline autoinjector supply go to www.allergy.org.au/members/adrenaline-autoinjector-availability

Continue reading

Hymenoptera® venom product supply update

9th March 2020

There is currently limited stock of Hymenoptera® Honey Bee venom in Australia and New Zealand. This is due to critical manufacturing issues at Jubilant HollisterStier LLC, which negatively impacts their ability to ship venoms outside of the USA in the short term. A further update on supply will be available in April 2020.

Stock of Paper Wasp and Yellow Jacket venom is not currently limited in Australia and New Zealand.

Due to the limited stock of Hymenoptera® Honey Bee venom it is recommended that commencement of Honey Bee venom immunotherapy in new patients is delayed until continuation of venom supply is assured.  Completion of Honey Bee venom immunotherapy may be considered in lower-risk patients who have completed three years of maintenance therapy, instead of continuing for five years.

For orders please contact Stallergenes Greer directly – for contact details go to www.allergy.org.au/members/insect-allergy

Continue reading

Updated ASCIA OIT for food allergy information

4 March 2020:

Oral immunotherapy (OIT) is a potential treatment for food allergy. It involves giving gradually increasing amounts of food allergen under medical supervision and continued daily consumption of the food allergen. If the goal of desensitisation is reached, there is a temporary increase in the amount of food allergen that can be consumed before an allergic reaction occurs.

OIT is an emerging treatment, and there are no OIT products for food allergies registered by the Therapeutic Goods Administration (TGA) in Australia or Medsafe in New Zealand. One OIT product for peanut allergy (PalforziaTM developed by the company Aimmune Therapeutics) has received Food and Drug Administration (FDA) approval for use in the USA in 2020.

ASCIA OIT for food allergy information for patients, consumers and carers has been updated and is now available on the ASCIA website www.allergy.org.au/patients/allergy-treatment/oral-immunotherapy-for-food-allergy

The main updates include:

It is important to note that current OIT methods are not a cure for food allergy. There are concerns about potential harm of OIT for food allergy outweighing the benefits in some people with severe food allergy, as well as considerable cost implications. This applies to OIT products that are registered as well as OIT used in clinical trials.

The benefits and harms of different forms of OIT are still being studied in clinical trials in Australia and globally. More data needs to be collected about safety, tolerability, cost-effectiveness, quality of life and long term outcomes.

Continue reading

Updated ASCIA HAE information

1 March 2020

ASCIA has updated its information on hereditary angioedema (HAE), to be consistent with international guidelines and include new treatments, and the following resources are now available on the ASCIA website www.allergy.org.au/hp/papers/hereditary-angioedema

  • Updated ASCIA HAE Position Paper.
  • New ASCIA HAE Management Plan (pdf with type in fields), which replaces the ASCIA HAE Action Plan.
  • New ASCIA HAE Case Peer Review Form (pdf with type in fields), which needs to be completed when requesting prophylaxis dose increases using a new treatment option - Berinert® SC.

For information regarding danazol supply in Australia please refer to www.allergy.org.au/about-ascia/info-updates/product-supply-update-danazol

Continue reading

Product supply update – danazol

28 February 2020

Danazol is used in some patients for the management of hereditary angioedema (HAE). Danazol (Azol) has recently been discontinued (in January 2020) in Australia by the supplier (Mylan, formerly Alphapharm), as reported on the TGA website https://apps.tga.gov.au/Prod/msi/Search/Details/danazol  Other brands of danazol may be sourced using a Special Acces Scheme (SAS) application to the TGA. Please refer below for further information.  In New Zealand danazol is still available from Mylan.  

For patients who will no longer be prescribed danazol, ASCIA recommends that they should gradually run down supplies and not stop suddenly, as this could result in increased HAE attacks. For example, they may half their usual dose until supply is finished.

All patients with HAE should have adequate supplies of Icatibant (Firazyr®) on hand, and if possible they should keep a written diary of HAE attacks for at least a month, as they may qualify for Berinert® SC.  

Access to other brands of danazol in Australia

The Therapeutic Goods legislation provides a number of avenues through which Australian residents and medical practitioners may access therapeutic goods which are not registered in Australia. One of these avenues is the Special Access Scheme (SAS), which refers to arrangements to allow for the import and/or supply of an unapproved therapeutic good for a single patient, on a case by case basis. To access unapproved danazol  via the SAS, a patient’s doctor can submit an application to the TGA. Further information regarding the SAS and the relevant application forms are available from the TGA website: https://www.tga.gov.au/form/special-access-scheme. Should the doctor have enquiries regarding the SAS, the doctor can email This email address is being protected from spambots. You need JavaScript enabled to view it..

As these products are not approved for marketing in Australia, the TGA is unable to vouch for the quality, safety or efficacy of unapproved products. Suppliers (sponsors) who have advised that they may be able to bring in danazol products under SAS are:

  • Medsurge Healthcare Pty Ltd – Ph: 1300 788 261
  • Link Medical Products Pty Ltd – 1800 181 060
  • HL Pharma Pty Ltd – 03 9823 6228

There may be other suppliers who can also supply danazol under SAS.

Continue reading

Supply update - EpiPen® Jr 150 microgram adrenaline (epinephrine) autoinjector

25 February 2020

Mylan Australia has advised that there has been sufficient supply of EpiPen® Jr 150 microgram adrenaline (epinephrine) autoinjectors since early February 2020 at wholesalers and at Mylan’s warehouse to meet current patient needs in Australia.

Orders from wholesalers and pharmacies are being filled as they are received. As a result, EpiPen® Jr has been removed from the Therapeutic Goods Administration (TGA) Medicines Shortage Information Initiative website.  Mylan Australia’s dedicated, toll-free EpiPen Customer Service hotline 1800 931 625 remains up and running for any enquiries.

To ensure that supply channels are aware of this news, Mylan has emailed the attached notice to pharmacists. The notice is also being distributed by the Pharmacy Guild of Australia and the Pharmaceutical Society of Australia.

pdfEpiPen supply update 24 Feb 2020160.28 KB

Mylan Australia thanks the allergy and anaphylaxis community for its patience during the recent supply shortage.

Continue reading

Pesto products recalled due to peanut contamination

21 February 2020

There have been several pesto products recalled in recent weeks because they contain an undeclared allergen (peanut). The peanuts were in one of the ingredients (cashews) used in these products.

Allergy & Anaphylaxis Australia (A&AA) has worked with Food Standards Australia New Zealand (FSANZ) and they have released a statement on the FSANZ website: www.foodstandards.gov.au/consumer/generalissues/Pages/-Undeclared-peanut-in-imported-pesto-products-containing-cashews.aspx

A&AA is continuing to work with industry stakeholders to find out where and how the contamination is occurring and they expect more products to be recalled in the near future.

Some manufacturers are now starting to return potentially contaminated products to shelf, with the addition of a precautionary allergen labelling (PAL) statement. It is important that consumers take PAL statements for peanut seriously when eating products containing cashew if they have a peanut allergy.  

Continue reading

More Articles ...

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.